MX2021013272A - Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. - Google Patents

Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.

Info

Publication number
MX2021013272A
MX2021013272A MX2021013272A MX2021013272A MX2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A
Authority
MX
Mexico
Prior art keywords
extracellular domain
fusion proteins
pharmaceutical formulations
formulations containing
present disclosure
Prior art date
Application number
MX2021013272A
Other languages
English (en)
Inventor
Yong Quan
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2021013272A publication Critical patent/MX2021013272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona composiciones farmacéuticas que comprenden moléculas de fusión de fragmento cristalizable (Fc) de dominio extracelular (ECD) de CD80. La presente descripción también proporciona métodos para tratar tumores sólidos mediante la administración de dichas composiciones farmacéuticas.
MX2021013272A 2019-05-03 2020-05-01 Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. MX2021013272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842722P 2019-05-03 2019-05-03
PCT/US2020/030946 WO2020227062A1 (en) 2019-05-03 2020-05-01 Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Publications (1)

Publication Number Publication Date
MX2021013272A true MX2021013272A (es) 2021-11-17

Family

ID=70847527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013272A MX2021013272A (es) 2019-05-03 2020-05-01 Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.

Country Status (9)

Country Link
US (1) US20220227834A1 (es)
EP (1) EP3963079A1 (es)
JP (1) JP2022531387A (es)
AR (1) AR118853A1 (es)
AU (1) AU2020270395A1 (es)
CA (1) CA3136831A1 (es)
MX (1) MX2021013272A (es)
TW (1) TW202108126A (es)
WO (1) WO2020227062A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180306A (es) 2015-11-02 2018-10-16 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
ES2899616T3 (es) 2017-04-28 2022-03-14 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180306A (es) 2015-11-02 2018-10-16 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer

Also Published As

Publication number Publication date
JP2022531387A (ja) 2022-07-06
CA3136831A1 (en) 2020-11-12
WO2020227062A1 (en) 2020-11-12
EP3963079A1 (en) 2022-03-09
AR118853A1 (es) 2021-11-03
AU2020270395A1 (en) 2021-12-23
US20220227834A1 (en) 2022-07-21
TW202108126A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
ZA202002094B (en) Trispecific proteins and methods of use
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
EA201991207A1 (ru) Новые агонисты tnfr и их применение
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2021013272A (es) Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
WO2020257278A3 (en) Small molecule target bromo/acetyl proteins and uses thereof
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro